JMP Says Forgotten Spruce Biosciences Could Draw Attention In 2023

  • JMP Securities initiated coverage on Spruce Biosciences, Inc. SPRB with a Market Outperform and a price target of $8.
  • The company's lead asset tildacerfont – a CRF1 receptor antagonist – could be a paradigm-changing therapeutic for the 20-30K adrenal hyperplasia (CAH) patients in the U.S. 
  • CAH is a rare autosomal recessive disease, resulting in reduced cortisol production. 
  • Tildacerfont has completed two Phase 2a trials showing proof of concept via reductions in disease biomarkers and a clean safety profile.
  • The company has designed its late-stage trials - CAHmelia-203 and -204 to focus on distinct patient populations, potentially improving the probability of success.
  • Recently, the company announced that CAHmelia-203 is approaching 50% enrollment, and CAHmelia-204 surpassed 25%.
  • Data from ‘203 are coming in 2H 2023, possibly derisking for ‘204 data slated for 2H 2024.
  • SPRB has also started a Phase 2 trial for pediatric CAH, reinforcing analysts' confidence in tildacerfont's safety profile, with initial data in 1H 2023.
  • Cash, cash equivalents, and short-term investments of $90.4 million at the end of Q3.
  • Price Action: SPRB shares are up 15.24% at $1.21 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CarePrice TargetInitiationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!